pheon therapeutics ltd Company Information
Company Number
09677410
Website
www.femtogenix.comRegistered Address
innovation house innovation way, discovery park, sandwich, kent, CT13 9FF
Industry
Research and experimental development on biotechnology
Telephone
02038580153
Next Accounts Due
December 2024
Group Structure
View All
Shareholders
research corporation technologies inc 28.1%
atlas venture fund xii l p 19.4%
View Allpheon therapeutics ltd Estimated Valuation
Pomanda estimates the enterprise value of PHEON THERAPEUTICS LTD at £1.1m based on a Turnover of £818.5k and 1.38x industry multiple (adjusted for size and gross margin).
pheon therapeutics ltd Estimated Valuation
Pomanda estimates the enterprise value of PHEON THERAPEUTICS LTD at £0 based on an EBITDA of £-10.4m and a 5.64x industry multiple (adjusted for size and gross margin).
pheon therapeutics ltd Estimated Valuation
Pomanda estimates the enterprise value of PHEON THERAPEUTICS LTD at £31.5m based on Net Assets of £14.1m and 2.24x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Pheon Therapeutics Ltd Overview
Pheon Therapeutics Ltd is a live company located in sandwich, CT13 9FF with a Companies House number of 09677410. It operates in the research and experimental development on biotechnology sector, SIC Code 72110. Founded in July 2015, it's largest shareholder is research corporation technologies inc with a 28.1% stake. Pheon Therapeutics Ltd is a young, small sized company, Pomanda has estimated its turnover at £818.5k with high growth in recent years.
Upgrade for unlimited company reports & a free credit check
Pheon Therapeutics Ltd Health Check
Pomanda's financial health check has awarded Pheon Therapeutics Ltd a 5 rating. We use a traffic light system to show it exceeds the industry average on 6 measures and has 3 areas for improvement. Company Health Check FAQs
6 Strong
2 Regular
3 Weak
Size
annual sales of £818.5k, make it smaller than the average company (£3m)
- Pheon Therapeutics Ltd
£3m - Industry AVG
Growth
3 year (CAGR) sales growth of 22%, show it is growing at a faster rate (13.1%)
- Pheon Therapeutics Ltd
13.1% - Industry AVG
Production
with a gross margin of 53.8%, this company has a comparable cost of product (53.8%)
- Pheon Therapeutics Ltd
53.8% - Industry AVG
Profitability
an operating margin of -1271.4% make it less profitable than the average company (-0.1%)
- Pheon Therapeutics Ltd
-0.1% - Industry AVG
Employees
with 4 employees, this is below the industry average (40)
4 - Pheon Therapeutics Ltd
40 - Industry AVG
Pay Structure
on an average salary of £71.2k, the company has an equivalent pay structure (£71.2k)
- Pheon Therapeutics Ltd
£71.2k - Industry AVG
Efficiency
resulting in sales per employee of £204.6k, this is more efficient (£126.8k)
- Pheon Therapeutics Ltd
£126.8k - Industry AVG
Debtor Days
it gets paid by customers after 15 days, this is earlier than average (52 days)
- Pheon Therapeutics Ltd
52 days - Industry AVG
Creditor Days
its suppliers are paid after 892 days, this is slower than average (60 days)
- Pheon Therapeutics Ltd
60 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Pheon Therapeutics Ltd
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 379 weeks, this is more cash available to meet short term requirements (34 weeks)
379 weeks - Pheon Therapeutics Ltd
34 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 11.5%, this is a lower level of debt than the average (50%)
11.5% - Pheon Therapeutics Ltd
50% - Industry AVG
PHEON THERAPEUTICS LTD financials
Pheon Therapeutics Ltd's latest turnover from March 2023 is estimated at £818.5 thousand and the company has net assets of £14.1 million. According to their latest financial statements, Pheon Therapeutics Ltd has 4 employees and maintains cash reserves of £13.4 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
Mar 2023 | Mar 2022 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
---|---|---|---|---|---|---|---|
Turnover | |||||||
Other Income Or Grants | |||||||
Cost Of Sales | |||||||
Gross Profit | |||||||
Admin Expenses | |||||||
Operating Profit | |||||||
Interest Payable | |||||||
Interest Receivable | |||||||
Pre-Tax Profit | |||||||
Tax | |||||||
Profit After Tax | |||||||
Dividends Paid | |||||||
Retained Profit | |||||||
Employee Costs | |||||||
Number Of Employees | 4 | 6 | 8 | 9 | 9 | 10 | 8 |
EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
Mar 2023 | Mar 2022 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
---|---|---|---|---|---|---|---|
Tangible Assets | 20,044 | 45,214 | 120,739 | 197,287 | 236,290 | 239,579 | 114,819 |
Intangible Assets | 0 | 0 | 1 | 79 | 157 | 235 | 313 |
Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Fixed Assets | 20,044 | 45,214 | 120,740 | 197,366 | 236,447 | 239,814 | 115,132 |
Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Debtors | 35,000 | 40,000 | 5,000 | 3,840 | 0 | 0 | 0 |
Group Debtors | 44,733 | 0 | 0 | 0 | 0 | 0 | 0 |
Misc Debtors | 2,406,448 | 110,708 | 146,401 | 144,536 | 377,672 | 355,169 | 190,380 |
Cash | 13,389,911 | 23,502,060 | 221,049 | 871,647 | 321,002 | 177,398 | 1,229,762 |
misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total current assets | 15,876,092 | 23,652,768 | 372,450 | 1,020,023 | 698,674 | 532,567 | 1,420,142 |
total assets | 15,896,136 | 23,697,982 | 493,190 | 1,217,389 | 935,121 | 772,381 | 1,535,274 |
Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Creditors | 924,318 | 252,049 | 51,430 | 238,584 | 49,282 | 80,978 | 23,773 |
Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other current liabilities | 908,794 | 116,382 | 75,451 | 71,413 | 74,940 | 28,352 | 21,173 |
total current liabilities | 1,833,112 | 368,431 | 126,881 | 309,997 | 124,222 | 109,330 | 44,946 |
loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other liabilities | 0 | 0 | 2,458,718 | 1,641,041 | 0 | 0 | 0 |
provisions | 0 | 0 | 0 | 33,552 | 40,196 | 26,674 | 23,026 |
total long term liabilities | 0 | 0 | 2,458,718 | 1,674,593 | 40,196 | 26,674 | 23,026 |
total liabilities | 1,833,112 | 368,431 | 2,585,599 | 1,984,590 | 164,418 | 136,004 | 67,972 |
net assets | 14,063,024 | 23,329,551 | -2,092,409 | -767,201 | 770,703 | 636,377 | 1,467,302 |
total shareholders funds | 14,063,024 | 23,329,551 | -2,092,409 | -767,201 | 770,703 | 636,377 | 1,467,302 |
Mar 2023 | Mar 2022 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | |
---|---|---|---|---|---|---|---|
Operating Activities | |||||||
Operating Profit | |||||||
Depreciation | 30,571 | 79,808 | 73,934 | 72,520 | 63,927 | 30,510 | 6,873 |
Amortisation | 0 | 1 | 78 | 78 | 78 | 78 | 78 |
Tax | |||||||
Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Debtors | 2,335,473 | 150,708 | 3,025 | -229,296 | 22,503 | 164,789 | 190,380 |
Creditors | 672,269 | 252,049 | -187,154 | 189,302 | -31,696 | 57,205 | 23,773 |
Accruals and Deferred Income | 792,412 | 116,382 | 4,038 | -3,527 | 46,588 | 7,179 | 21,173 |
Deferred Taxes & Provisions | 0 | 0 | -33,552 | -6,644 | 13,522 | 3,648 | 23,026 |
Cash flow from operations | |||||||
Investing Activities | |||||||
capital expenditure | |||||||
Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
cash flow from investments | |||||||
Financing Activities | |||||||
Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other long term liabilities | 0 | 0 | 817,677 | 1,641,041 | 0 | 0 | 0 |
share issue | |||||||
interest | |||||||
cash flow from financing | |||||||
cash and cash equivalents | |||||||
cash | -10,112,149 | 23,502,060 | -650,598 | 550,645 | 143,604 | -1,052,364 | 1,229,762 |
overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
change in cash | -10,112,149 | 23,502,060 | -650,598 | 550,645 | 143,604 | -1,052,364 | 1,229,762 |
pheon therapeutics ltd Credit Report and Business Information
Pheon Therapeutics Ltd Competitor Analysis
Perform a competitor analysis for pheon therapeutics ltd by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other small companies, companies in CT13 area or any other competitors across 12 key performance metrics.
pheon therapeutics ltd Ownership
PHEON THERAPEUTICS LTD group structure
Pheon Therapeutics Ltd has no subsidiary companies.
Ultimate parent company
PHEON THERAPEUTICS LTD
09677410
pheon therapeutics ltd directors
Pheon Therapeutics Ltd currently has 7 directors. The longest serving directors include Mr Shaun Kirkpatrick (Sep 2015) and Mr Jonathan Tobin (Mar 2022).
officer | country | age | start | end | role |
---|---|---|---|---|---|
Mr Shaun Kirkpatrick | United States | 55 years | Sep 2015 | - | Director |
Mr Jonathan Tobin | United Kingdom | 41 years | Mar 2022 | - | Director |
President Michael Gladstone | United States | 38 years | Mar 2022 | - | Director |
Dr Rogier Rooswinkel | Netherlands | 41 years | Mar 2022 | - | Director |
Dr Rogier Rooswinkel | Netherlands | 41 years | Mar 2022 | - | Director |
Mr Jeffery Albers | United Kingdom | 53 years | Jan 2023 | - | Director |
Mr Cyrus Mozayeni | United Kingdom | 50 years | Jul 2023 | - | Director |
P&L
March 2023turnover
818.5k
+35%
operating profit
-10.4m
0%
gross margin
53.9%
+9.4%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2023net assets
14.1m
-0.4%
total assets
15.9m
-0.33%
cash
13.4m
-0.43%
net assets
Total assets minus all liabilities
pheon therapeutics ltd company details
company number
09677410
Type
Private limited with Share Capital
industry
72110 - Research and experimental development on biotechnology
incorporation date
July 2015
age
9
incorporated
UK
accounts
Total Exemption Full
ultimate parent company
previous names
femtogenix ltd (August 2022)
last accounts submitted
March 2023
address
innovation house innovation way, discovery park, sandwich, kent, CT13 9FF
accountant
KRESTON REEVES LLP
auditor
-
pheon therapeutics ltd Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to pheon therapeutics ltd.
pheon therapeutics ltd Companies House Filings - See Documents
date | description | view/download |
---|